Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.49 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7329171 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2PTGES | |
| SCHEMBL7329173 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2PTGES | |
| SCHEMBL23247964 | 0.97 | RAB9A (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL28152181 | 0.97 | RAB9A (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL204876 | 0.87 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL12509692 | 0.87 | HCRTR1 (0.46) | HCRTR1HCRTR2PTGES | |
| SCHEMBL14985689 | 0.87 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2707183 | 0.87 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL28590669 | 0.87 | USP30 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL19400821 | 0.87 | PRCP (0.52) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| WO-2016001820-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001820-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2016-01-07 | — | — | WO | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | HCRTR1 3869/4885HCRTR2 4436/4885PTGES 622/4885 |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, IMPA1 | HCRTR1 3945/4885HCRTR2 4460/4885PTGES 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.